Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies
| Autor: | Amelie Chabrol, Matthieu Mahévas, Bertrand Godeau, Marc Michel, Nicolas Limal, Laetitia Languille, Mehdi Khellaf, Philippe Bierling, Françoise Roudot-Thoraval |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
Lupus erythematosus Second line treatment Anti-nuclear antibody biology business.industry Hydroxychloroquine Hematology medicine.disease Gastroenterology Surgery immune system diseases Prednisone hemic and lymphatic diseases Internal medicine Concomitant medicine biology.protein Young adult Antibody skin and connective tissue diseases business medicine.drug |
| Zdroj: | American Journal of Hematology. 89:194-198 |
| ISSN: | 0361-8609 |
| DOI: | 10.1002/ajh.23609 |
| Popis: | Treatment of patients with lupus-associated thrombocytopenia (SLE-ITP) is not standardized. We report data on efficacy and safety of hydroxychloroquine (HCQ) in this setting and in ITP patients with positive antinuclear antibodies (ANA) without definite SLE. Inclusion criteria were: definite diagnosis of ITP with a platelet count (PLT) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text